Skip to main content
Search
Main content
David Klenerman

Prof Sir David Klenerman

(FMedSci FRS)

Group Leader

Determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies

Techniques

Advanced microscopy & imaging, Biophysical techniques, Fluid biomarkers, Software development

Biography

Professor Sir David Klenerman is a physical chemist who graduated and completed his doctorate at Cambridge University working with Professor Ian Smith on infra-red chemiluminescence for his PhD in 1985. This was followed by postdoctoral research at Stanford University, California with Professor Dick Zare on high overtone chemistry. He then returned to the UK and worked for seven years for BP Research in their Laser Spectroscopy Group before returning to the Department of Chemistry, University of Cambridge, progressing to a Professorship. At Cambridge his work has focussed on the development and application of physical methods, particularly laser spectroscopy and single molecule fluorescence, to biological and biomedical problems.  

His recognition includes being knighted by the Queen in 2018, for development of high speed DNA sequencing, and being awarded the Royal Society’s Royal Medal in 2018. He was awarded the 2020 Millennium Technology Prize jointly with Shankar Balasubramanian and the 2022 Breakthrough Prize for Life Sciences and 2024 Gairdner Prize for Life Sciences jointly with Shankar Balasubramanian and Pascal Mayer for next generation DNA  sequencing.

News

Key publications

Nature communications
Published
ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases
Authors
Evgeniia Lobanova, Yu P Zhang, Derya Emin, Jack Brelstaff, Lakmini Kahanawita, Maura Malpetti, Annelies Quaegebeur, Kathy Triantafilou, Martha Triantafilou, Henrik Zetterberg, James B Rowe, Caroline H Williams-Gray, Clare Elizabeth Bryant, David Klenerman
ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases
Science (New York, N.Y.)
Published
Aggregate-selective removal of pathological tau by clustering-activated degraders
Authors
Jonathan Benn, Shi Cheng, Sophie Keeling, Annabel E Smith, Marina J Vaysburd, Dorothea Böken, Lauren V C Miller, Taxiarchis Katsinelos, Catarina Franco, Elian Dupré, Clément Danis, Isabelle Landrieu, Luc Buée, David Klenerman, Leo C James, William A McEwan
Aggregate-selective removal of pathological tau by clustering-activated degraders
PLoS biology
Published
Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's disease
Authors
Rikesh M Rajani, Robert Ellingford, Mariam Hellmuth, Samuel S Harris, Orjona S Taso, David Graykowski, Francesca Kar Wey Lam, Charles Arber, Emre Fertan, John S H Danial, Matthew Swire, Marcus Lloyd, Tatiana A Giovannucci, Mathieu Bourdenx, David Klenerman, Robert Vassar, Selina Wray, Carlo Sala Frigerio, Marc Aurel Busche
Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's disease

Klenerman Lab

Explore the work of the Klenerman Lab focused on determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies.

Klenerman culture